Abstract
In this article, opinions were expressed on the improvement of early-stage diagnostic factors and the optimal pathways of therapeutic treatment, having determined the characteristics of heterogeneous neurohumorals of metabolic syndrome, the clinical manifesto of the disease. The analysis of the study shows that the issues of pathogenesis, clinical features of improving the effectiveness of medicamentous therapy, and treatment-rehabilitation aspects have not been studied perfectly so far. In patients with metabolic syndrome, hypotensive, anti-adipose agents, as well as treatment of statins and improvement of the prophylactic order of prevention of diseases, the issues of which were not studied at the end were discussed.
Highlights
The main pathogenetic mechanisms of the development of metabolic syndrome are related to the interaction of adipose tissue secretory activity, neurohumoral, adrenergic, The USA Journals Volume 03 Issue 05-2021 inflammatory mechanisms, cardiovascular remodeling, as well as the degree of their participation in the progression of MS
The role of high-level ANCA antineutrophil autoantibodies as predictors in the early stages of ED development in patients with metabolic syndrome has been demonstrated in patients with metabolic syndrome, as well as in early remodeling of the cardiovascular system
With the early development of left ventricular hypertrophy, the predictor of cardiac remodeling and an increase in the level of autoantibodies to COM-02 cardiomyocytes, which increase the rate of myocardial dystrophy, have been shown
Summary
The main pathogenetic mechanisms of the development of metabolic syndrome are related to the interaction of adipose tissue secretory activity, neurohumoral, adrenergic, The USA Journals Volume 03 Issue 05-2021 inflammatory mechanisms, cardiovascular remodeling, as well as the degree of their participation in the progression of MS. Leptin receptors have been shown to cause the 5 mechanism of early development of leptin resistance. The role of high-level ANCA antineutrophil autoantibodies as predictors in the early stages of ED development in patients with metabolic syndrome has been demonstrated in patients with metabolic syndrome, as well as in early remodeling of the cardiovascular system. With the early development of left ventricular hypertrophy, the predictor of cardiac remodeling and an increase in the level of autoantibodies to COM-02 cardiomyocytes, which increase the rate of myocardial dystrophy, have been shown. Blockade of insulin receptors by autoantibodies has been identified as a mechanism for the development of insulin resistance. The system of treatment of patients with MS diagnosed with arterial hypertension, obesity, dyslipidemia with antihypertensive, anti-adipose and hypolipidemic drugs is pathogenetically based on the desire to improve the complex therapy of MS
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The American Journal of Medical Sciences and Pharmaceutical Research
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
